TY - JOUR T1 - 拉脱维亚多药和广泛耐药结核患者的最终治疗结果接收包含delamanid治疗方案JF - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.01105-2017 VL - 50 - 5 SP -1701105 AU - Kuksa，西甲AU - Barkane，琳达AU - Hittel，诺伯特AU - 古普塔，拉杰什Y1 - 2017年11月1日UR - //www.qdcxjkg.com/content/50/5/1701105.abstract N2- Latvia is a high-priority country in the fight against tuberculosis (TB) in Europe, with an estimated TB incidence of 41 per 100 000 in 2015 [1]. In spite of an improving TB control programme [2] and cure rates reaching 80% for new and retreatment TB cases notified in 2014, multidrug-resistant (MDR-) TB (defined as TB resistant to rifampicin and isoniazid) rates in Latvia remain high [1]. An estimated 8% of new cases and 30% of retreatment TB cases were at least rifampicin-resistant (RR) in 2015 [1]. Cure rates in Latvia were 68% for the 2013 RR/MDR-TB cohort [1]. Of all the MDR-TB patients registered in 2015, 25% had extensively drug-resistant (XDR-) TB (defined as MDR-TB with additional resistance to a fluoroquinolone and a second-line injectable drug) [1].Final treatment outcomes from the first cohort of delamanid MDR-TB patients in Latvia support its safety and efficacy http://ow.ly/6Mhy30fPv2f ER -